Views: 1,275 | Downloads:
28
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Clinical Activity and Benefit of Irinotecan (CPT-11) in Patients with Metastatic Colorectal Carcinoma Pretreated with Fluorouracil-Based Chemotherapy .
Ratanatharathorn V 
,
Sirachainan E ,
Jirajarus M ,
Sirilerttrakul S
,
Sirachainan E ,
Jirajarus M ,
Sirilerttrakul S The purpose of this prospective study was to assess the efficacy, clinical benefit and safety
of irinotecan (CPT -11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer
(CRC). Sixteen patients with World Health Organization (WHO) performance status
s:
2 were
treated with CPT-11 350 mg/m
2
every 3 weeks. The observed partial response (PR) rate was 6.3
per cent with a high rate of stable disease (SD) ( 43.7%) which was of long duration (21.1 weeks
for the best response ; 1PR, 7SD). The median survival time for the 16 patients entered into this
study was 69.6 weeks. There was no toxic death. The most frequent adverse events were neutro-
penia (31% grade 3/4) and delayed diarrhea (9.7%). CPT-II has definite activity in the treatment
of progressive metastatic CRC truly resistant to 5-FU which translated into clinical survival
benefit. Median survival from first administration of CPT-II was 78.6 weeks for patients with
best response (PR+SD) compared with 28.1 weeks for patients with progressive disease (PD)
(P=O.Ol). With the appearance of new active drugs in this highly chemotherapy-resistant disease.
the definition of response should be reassessed in CRC.
Key word : Advanced Colorectal Cancer (CRC), Irinotecan
of irinotecan (CPT -11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer
(CRC). Sixteen patients with World Health Organization (WHO) performance status
s:
2 were
treated with CPT-11 350 mg/m
2
every 3 weeks. The observed partial response (PR) rate was 6.3
per cent with a high rate of stable disease (SD) ( 43.7%) which was of long duration (21.1 weeks
for the best response ; 1PR, 7SD). The median survival time for the 16 patients entered into this
study was 69.6 weeks. There was no toxic death. The most frequent adverse events were neutro-
penia (31% grade 3/4) and delayed diarrhea (9.7%). CPT-II has definite activity in the treatment
of progressive metastatic CRC truly resistant to 5-FU which translated into clinical survival
benefit. Median survival from first administration of CPT-II was 78.6 weeks for patients with
best response (PR+SD) compared with 28.1 weeks for patients with progressive disease (PD)
(P=O.Ol). With the appearance of new active drugs in this highly chemotherapy-resistant disease.
the definition of response should be reassessed in CRC.
Key word : Advanced Colorectal Cancer (CRC), Irinotecan
Download:
PDF